Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Ruxolitinib cream for vitiligo Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Vitiligo Dermatology 2021 View  |  Download
Ruxolitinib for acute graft versus host disease (aGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for chronic graft versus host disease (cGvHD) Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2019 View  |  Download
Ruxolitinib for grades II-IV treatment-naïve or steroid-refractory acute graft versus host disease Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
Ruxolitinib for treating chronic graft versus host disease after allogeneic stem cell transplant in paediatric patients Ruxolitinib (Jakavi; INCB018424; CTP-543; ruxolitinib phosphate) Graft versus host disease (GvHD) Immunology 2023 View  |  Download
SA-237 for neuromyelitis optica and neuromyelitis optica spectrum disorders Satralizumab (SA237; RG6168) Neuromyelitis optica , Neuromyelitis optica spectrum disorders Neurology , Ophthalmology 2017 View  |  Download
Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line Azacitidine (Vidaza; CC-486) , Sabatolimab (MBG453) Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
1 2 91 92 93 94 95 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications